Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Trial
Authors:
- 1 December 1999
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 75 (3) , 444-446
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.Journal of Clinical Oncology, 1998
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian CancerGynecologic Oncology, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.Journal of Clinical Oncology, 1996
- Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.Journal of Clinical Oncology, 1996
- Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.Journal of Clinical Oncology, 1995
- Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.Journal of Clinical Oncology, 1995
- Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.Journal of Clinical Oncology, 1994
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.Journal of Clinical Oncology, 1992